title: [Acetylsalicylic acid non-responders after ischemic insult in geriatric patients].
abstract: BACKGROUND
  The cardiovascular and cerebral ischemic risk is defined as the risk of suffering a thromboembolic event. The common secondary prophylaxis is still the use of acetylsalicylic acid (ASA). The usual daily dose is 100 mg. Efficacy concerning platelet aggregation is not routinely checked.
  
  
  METHODS
  In this study, patients taking 100 mg aspirin daily (orally) were examined after admittance to the stroke unit due to a stroke or stroke recurrence. Platelet aggregation was performed using a Platelet Function Analyser (PFA 100).
  
  
  RESULTS
  A total of 71 patients were examined, 53(73%) had experienced a primary ischemic insult, and 18(25.4%) stroke recurrence. Patients with prolonged closure time in the collagen/epinephrine cell (normal range 85-165 s) were classified as responders to ASA, while 14 (19.7%) were classified as non-responders.
  
  
  CONCLUSIONS
  It remains open whether the secondary prophylaxis or a more effective inhibition of platelet aggregation results in the improved protection against a future event.
authors.affiliation: Helios Klinikum Berlin Buch, Schwanebecker Chaussee 50, 13125, Berlin, Deutschland, matylda.nosul@helios-kliniken.de.
authors.forename: M
authors.initials: M
authors.lastname: Nosul
authors.forename: G F
authors.initials: GF
authors.lastname: Kolb
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001241:Aspirin / Q000627:therapeutic use*; D002545:Brain Ischemia / Q000097:blood / Q000175:diagnosis* / Q000517:prevention & control*; D005260:Female; D006801:Humans; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D010979:Platelet Function Tests; D012008:Recurrence; D055502:Secondary Prevention; D020521:Stroke / Q000097:blood / Q000175:diagnosis* / Q000517:prevention & control*; D017211:Treatment Failure
chemical_list: D010975:Platelet Aggregation Inhibitors; D001241:Aspirin